Top 10 Companies in Global Cancer Cachexia Market in (2025–2035): Expert View by Spherical Insights
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The global cancer cachexia market refers to a set of therapies and medical solutions for the management of cancer cachexia, a multifactorial metabolic disorder involving profound involuntary weight loss and progressive skeletal muscle depletion. The driving factors for the cancer cachexia market are the rising prevalence of cancer and the need for targeted therapeutic agents for cancer. The symptoms such as appetite stimulants, progestogens, corticosteroids, and combination therapy. The major application area includes the management of severe weight loss, muscular disorders, and metabolic disorders.
The cancer cachexia accounts for nearly 20% of global cancer-related deaths, underscoring its clinical and economic significance. The rising burden is driving demand for targeted therapies and supportive care solutions.
The innovations form of new drugs with metabolic targets such as ponsegromab and S-pindolol benzoate, as well as anti-inflammatory drugs. The opportunities in the global market for cancer cachexia include the implementation of personalized approaches, AI in drug development, long-acting drug delivery systems, and the implementation of multimodal approaches in the management of the condition in order to improve the quality of life of the patients.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of theCancer Cachexia Market
Cancer Cachexia Market Size & Statistics
- The Market Size for Cancer Cachexia Market Was Estimated to be worth USD 2.07 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 5.65% between 2025 and 2035.
- The Global Cancer Cachexia Market Size is anticipated to reach USD 3.79 Billion by 2035.
- North America is estimated to generate the highest demand during the forecast period in the Global Cancer Cachexia Market.
- Asia Pacific is projected to grow the fastest during the forecast period in The Global Cancer Cachexia Market.
Global Cancer Cachexia Market Size, Share, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025–2035
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the cancer cachexia market. This is due to the rising cancer burden, expanding healthcare infrastructure, and increasing healthcare expenditure across emerging economies such as China and India. Growing awareness of supportive cancer care, improving access to advanced treatments, and ongoing investments in oncology research are further accelerating regional market growth.
North America is anticipated to generate the highest demand during the forecast period in the cancer cachexia market. This is due to the high prevalence of cancer, advanced healthcare infrastructure, and strong adoption of innovative therapies for cachexia management. The presence of leading pharmaceutical companies, robust research and development activities, and favorable reimbursement policies further support market growth. Additionally, increasing awareness of supportive cancer care and improved diagnostic capabilities continue to drive demand for cancer cachexia treatments across the region.
Ready to lead the Cancer Cachexia Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 trends in the cancer cachexia market
- Shift to Early-Stage Intervention & Pre-cachexia Screening
- Growth of Multimodal Therapy Models
- Pipeline Shift Toward Novel Mechanisms
- Rise of Ghrelin Receptor Agonists
- Integration of Immuno-Oncology and Cachexia Therapy
- Precision Nutrition and Metabolomics
- Increased Role of Digital Health and Remote Monitoring
- Strategic Partnerships Between Pharma and Nutrition Companies
- Expansion of Homecare and Palliative Services
- Regulatory Focus on New Endpoints
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of theCancer Cachexia Market
- Shift to Early-Stage Intervention & Pre-cachexia Screening
With 60% of clinicians incorporating cachexia management into initial treatment plans to prevent muscle loss rather than trying to reverse it at late stages, oncology specialists are moving their attention from managing end-stage wasting to acting earlier.
- Growth of Multimodal Therapy Models
The market is shifting from monotherapy to a combination strategy that incorporates resistance training, specific nutrition, and pharmaceutical interventions. This is becoming the therapeutic trend with the fastest rate of growth.
- Pipeline Shift Toward Novel Mechanisms
Selective Androgen Receptor Modulators (SARMs), IL-6 inhibitors, and anti-myostatin antibodies (such as Actimed Therapeutics' S-pindolol benzoate) are examples of muscle-protective mechanisms that are replacing appetite stimulants (such megestrol acetate) in drug research.
- Rise of Ghrelin Receptor Agonists
Anamorelin and other ghrelin receptor agonists are becoming popular for boosting appetite and reversing muscular atrophy; a number of these drugs are in advanced clinical trials that target the metabolic pathways involved in cachexia.
- Integration of Immuno-Oncology and Cachexia Therapy
The frequency of cachexia rises as immunotherapy raises cancer survival rates. To increase treatment tolerance and survival rates, companies are investigating the co-positioning of cachexia treatments with checkpoint inhibitors.
Top 10 Companies Leading the cancer cachexia market
- Pfizer Inc.
- Helsinn Group
- Actimed Therapeutics
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Novartis AG
- AVEO Oncology
- Endevica Bio
- Merck & Co., Inc.
- Aeterna Zentaris Inc.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of theCancer Cachexia Market
1. Pfizer Inc.
Headquarters: New York City
Pfizer Inc., a company founded in 1849, currently has a workforce of 88,000 employees worldwide. Its revenue for the year 2025 stood at approximately USD 58 to 60 billion. In the cancer cachexia market, the contribution of Pfizer would come from its strong portfolio of cancer and supportive care products, as the company’s products find use in the treatment of cancer, thereby indirectly contributing to the treatment of cachexia.
2. Helsinn Group
Headquarters: Lugano, Switzerland
The Helsinn Group, which was founded in 1976 and has approximately 350 to 400 employees worldwide, has generated USD 25-75 million in revenues approximately in 2025. In the global market for cancer cachexia, Helsinn contributes to the treatment with its supportive oncology portfolio, including products like Adlumiz (anamorelin) and Akynzeo, which are used to manage the symptoms of cancer.
3. Actimed Therapeutics
Headquarters: Ascot, Berkshire, United Kingdom
The Actimed Therapeutics, founded in 2017, has a small workforce of approximately 9-10 employees. The company, a biotechnology firm in the clinical stage, has limited early-stage revenue, which will be less than 10 million USD by 2025. In the field of cancer cachexia therapy, Actimed develops innovative therapies such as its lead candidate, S-pindolol benzoate, known as ACM-001.1.
4. Bristol-Myers Squibb Company
Headquarters: Princeton, New Jersey, United States
The Bristol-Myers Squibb Company, founded in 1887, has around 32,500 employees worldwide. The company generated a revenue of around USD 48.2 billion in 2025. In the global cancer cachexia market, Bristol-Myers Squibb Company is involved in developing supportive oncology treatments with its advanced cancer therapies such as Opdivo, Yervoy, and Reblozyl, which are used to manage cancer and its complications.
5. Eli Lilly and Company
Headquarters: Indianapolis, Indiana, United States
The Eli Lilly and Company, which was founded in 1876 and currently has approximately 47,000 employees across the globe, recorded a revenue of approximately USD 45-46 billion in 2025. In the context of the global market for cancer cachexia, the contribution of the pharmaceutical company Eli Lilly is based on the range of treatments that the company offers under the umbrella of cancer treatments, which include the management of the complications that arise as a result of cancer.
Are you ready to discover more about the cancer cachexia market?
The report provides an in-depth analysis of the leading companies operating in the global cancer cachexia market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Pfizer Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Helsinn Group
- Actimed Therapeutics
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Novartis AG
- AVEO Oncology
- Endevica Bio
- Merck & Co., Inc.
- Aeterna Zentaris Inc.
- Others.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of theCancer Cachexia Market
Conclusion
The global market for cancer cachexia has tremendous growth prospects, with the market expected to grow from USD 2.07 billion in 2024 to USD 3.79 billion by 2035 at a CAGR of 5.65%. The market growth can be attributed to the growing global prevalence of cancer, which has created an increased demand for effective drugs to treat this condition. Cancer cachexia contributes to 20% of total deaths due to cancer. The development of new drugs, such as ponsegromab and S-pindolol benzoate, which target metabolism, has given the market a new direction in the treatment of this condition. Today, the market is shifting towards multimodal therapy to treat this condition, which improves the quality of life for patients with cancer cachexia. North America will drive the global market due to its well-established healthcare infrastructure, followed by the Asia-Pacific region, which will exhibit the highest growth rate due to increased investment in healthcare.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Follow Us: LinkedIn | Facebook | Twitter
Need help to buy this report?